down arrow

Hoth Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US44148G2049
USD
1.19
0.05 (4.39%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.161.22

52 Week

0.663.80
Valuation
Technical
Day's Volume

CASH

103.76 k

Shareholding (Jun 2025)

FII

0.32%

Held by 6 FIIs

DII

98.45%

Held by 1 DIIs

Promoter

0.00%

How big is Hoth Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Hoth Therapeutics, Inc. has a market capitalization of 17.17 million, with net sales of 0.00 million and a net profit of -9.62 million over the last four quarters. The company reported shareholder's funds of 6.88 million and total assets of 7.71 million as of Dec 24.

Market Cap: As of Jun 18, Hoth Therapeutics, Inc. has a market capitalization of 17.17 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Hoth Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -9.62 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 6.88 million and total assets of 7.71 million.

Read More

What does Hoth Therapeutics, Inc. do?

22-Jun-2025

Hoth Therapeutics, Inc. is a micro-cap biopharmaceutical company focused on developing targeted therapeutics for conditions like atopic dermatitis. As of March 2025, it reported a net profit loss of $3 million and has a market cap of $17.17 million.

Overview: <BR>Hoth Therapeutics, Inc. is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 17.17 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.98 <BR>Return on Equity: -83.39% <BR>Price to Book: 1.49<BR><BR>Contact Details: <BR>Address: 701 S Carson St Ste 200, NEW YORK NY: 10020-2003 <BR>Tel: 1 551 5782261 <BR>Website: https://hoththerapeutics.com/

Read More

Is Hoth Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Hoth Therapeutics, Inc. has shifted to a bullish trend supported by positive weekly indicators, despite a bearish monthly RSI, and has outperformed the S&P 500 with a 90.10% return over the past year.

As of 3 September 2025, the technical trend for Hoth Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the Bollinger Bands and daily moving averages indicate a bullish stance. However, the monthly RSI is bearish, which introduces some caution. The overall strength of the bullish trend is supported by the weekly KST and Dow Theory, both showing mild bullishness. <BR><BR>In terms of performance, Hoth Therapeutics has significantly outperformed the S&P 500 over the past year with a return of 90.10% compared to the S&P 500's 17.14%, and it has also shown strong returns of 48.84% over the last month versus the S&P 500's 2.33%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 19 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.92

stock-summary
Return on Equity

-104.59%

stock-summary
Price to Book

2.00

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.53%
0%
-10.53%
6 Months
29.38%
0%
29.38%
1 Year
37.8%
0%
37.8%
2 Years
2.59%
0%
2.59%
3 Years
-69.57%
0%
-69.57%
4 Years
-93.61%
0%
-93.61%
5 Years
-97.31%
0%
-97.31%

Hoth Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Hoth Therapeutics, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Hoth Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the Bollinger Bands and daily moving averages indicate a bullish stance. However, the monthly RSI is bearish, which introduces some caution. The overall strength of the bullish trend is supported by the weekly KST and Dow Theory, both showing mild bullishness. In terms of performance, Hoth Therapeutics has significantly outperformed the S&P 500 over the past year with a return of 90.10% compared to the S&P 500's 17.14%, and it has also shown strong returns of 48.84% over the last month versus the S&P 500's 2.33%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-0.49%
EBIT to Interest (avg)
-9.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.98
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.49%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.49
EV to EBIT
-0.61
EV to EBITDA
-0.61
EV to Capital Employed
5.88
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-963.73%
ROE (Latest)
-83.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.23%)

Foreign Institutions

Held by 6 Foreign Institutions (0.32%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 37.14% vs -45.83% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.20",
          "val2": "-3.50",
          "chgp": "37.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-3.50",
          "chgp": "37.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -5.13% vs 31.58% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.20",
          "val2": "-7.70",
          "chgp": "-6.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.20",
          "val2": "-7.80",
          "chgp": "-5.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.20
-3.50
37.14%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.20
-3.50
37.14%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 37.14% vs -45.83% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-8.20
-7.70
-6.49%
Interest
0.00
0.00
Exceptional Items
-0.00
-0.20
100.00%
Consolidate Net Profit
-8.20
-7.80
-5.13%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -5.13% vs 31.58% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Hoth Therapeutics, Inc. stock-summary
stock-summary
Hoth Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. The Company is engaged in developing and commercializing the BioLexa Platform. BioLexa Platform is a proprietary, patented antimicrobial therapy. The BioLexa Platform traps all the zinc ions by adding a chelator called DTPA, which prevents Staph biofilm formation. It intends to explore the use of the BioLexa Platform for the treatment of atopic dermatitis, or eczema. It also focuses on exploring the use of the BioLexa Platform in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures.
Company Coordinates stock-summary
Company Details
701 S Carson St Ste 200 , NEW YORK NY : 10020-2003
stock-summary
Tel: 1 551 5782261
stock-summary
https://hoththerapeutics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."